Focused On-demand Library for Large ribosomal subunit protein uL22m

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q9NWU5

UPID:

RM22_HUMAN

Alternative names:

39S ribosomal protein L22, mitochondrial; 39S ribosomal protein L25, mitochondrial

Alternative UPACC:

Q9NWU5; A6NGJ8; Q5H9Q1; Q96Q51; Q9P006

Background:

The Large ribosomal subunit protein uL22m, also known as 39S ribosomal protein L22 or L25, mitochondrial, plays a crucial role in the mitochondrial ribosome. It is part of the 39S large ribosomal subunit and is involved in protein synthesis within mitochondria. The protein's alternative names highlight its significance in the mitochondrial ribosomal structure, underscoring its essential function in mitochondrial biology.

Therapeutic significance:

Understanding the role of Large ribosomal subunit protein uL22m could open doors to potential therapeutic strategies. Its pivotal role in mitochondrial protein synthesis makes it an intriguing subject for scientific inquiry, with the potential to uncover novel therapeutic targets for diseases linked to mitochondrial dysfunction.